We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Greiner Bio-One

Download Mobile App




Rechargeable Neuromodulation Implant Treats Bowel Dysfunction

By HospiMedica International staff writers
Posted on 02 Oct 2019
Print article
Image: The r-SNM implantable sacral neuromodulation device (Photo courtesy of Axonics).
Image: The r-SNM implantable sacral neuromodulation device (Photo courtesy of Axonics).
A novel implantable sacral neuromodulation (SNM) device is designed to aid patients suffering from fecal incontinence, overactive bladder (OAB), and urinary retention.

The Axonics Modulation Technologies (Irvine, CA, USA) rechargeable SNM (r-SNM) system offers a long-lived miniaturized neurostimulator, approximately the size of a USB stick that can last for up to 15 years in the body. Features include a patented tined lead and user-friendly accessories. Key features include a wireless charging system optimized for infrequent charging, a small easy-to-use patient remote control, and an intuitive clinician programmer that facilitates lead placement and stimulation programming.

The system works by imitating a signal sent via the central nervous system (CNS) when the nerves in the sacral area and the brain no longer communicate effectively, thus leading to a bowel and/or bladder disorder. By stimulating the sacral nerve, a neurological signal is sent that manipulates a contraction within the pelvic floor. Over time, these contractions rebuild the strength of the organs and muscles, alleviating or eliminating symptoms of OAB and of the urinary or fecal disorder.

“Axonics has successfully developed a unique product to deliver SNM therapy that we believe will greatly improve the patient and clinician experience. It also features quick, safe charging capability and a patient-friendly wireless remote control,” said Raymond Cohen, CEO of Axonics. “We believe the number of patients seeking SNM treatment will expand dramatically over the next few years given our fuss-free, long-lived, full body MRI-compatible device.”

OAB affects more than 37 million people in the United States alone, with a significant impact on the quality of life of suffers by affecting a person’s social activities, exercise regimen, and by causing disruptive nighttime voiding. Despite this, only 33% of those suffering seek treatment, and as many as 70% stop using their medication within six months due to intolerable side effects or unsatisfying results.

Related Links:
Axonics Modulation Technologies


Print article

Channels

Copyright © 2000-2019 Globetech Media. All rights reserved.